Arcus Biosciences RCUS
NYSE RCUS
$25.83 +0.00 (+0.00%)
As of: Oct 1, 2026 · 2:03 PM EDT

Arcus Biosciences (RCUS) Preferred Stock Liabilities (2017)

Updated

Arcus Biosciences' Preferred Stock Liabilities was $226.2 million in Q4 2017.

Analysis

Arcus Biosciences (RCUS) Preferred Stock Liabilities (2017) Analysis & Trends

  • In earlier years, Preferred Stock Liabilities was $119.45 million in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Arcus Biosciences 3.28 Bn -53.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2017 226.20 Mn
API Access

Arcus Biosciences Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=RCUS&period=max&api_key=YOUR_API_KEY